A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Study on Aspirin for Preventing Recurrence of HER2 Negative Breast Cancer

Recruiting
18 years - 69 years
All
Phase N/A
1 Location

Brief description of study.

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy.

Detailed description of study

The purpose of this study is to compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: breast cancer
  • Age: 18 years - 69 years
  • Gender: All

Inclusion Criteria
Histologic documentation of women or men with node positive, HER2 negative, anatomic stage II or III breast carcinoma within one year of diagnosis and free of recurrence. If neoadjuvant therapy was received, either initial clinical stage (determined by physical and or radiologic examination) or post-operative pathologic stage can be used for eligibility purposes, with the higher stage determining eligibility. Histologic documentation of node positivity is required
Any ER/PgR status allowed
Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined the treating physician, is allowed. The last dose of chemotherapy or radiation therapy must be at least 60 days prior to study registration. Concurrent hormonal therapy will be allowed
Regular NSAID/aspirin use (defined as ? 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for one year prior to study entry and throughout the study period. Participants will be encouraged to use acetaminophen for minor pain and fever
Patients must be enrolled within 1 year after diagnosis
ECOG performance status 0-2
Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention
For patients who are Helicobacter pylori positive, a course of Helicobacter pylori eradication treatment must have been completed
Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use
Exclusion Criteria
History of GI bleeding requiring a blood transfusion, endoscopic or operative intervention
History of any prior stroke (hemorrhagic or ischemic)
Concurrent anticoagulation with warfarin or heparin or clopidogrel or oral direct thrombin inhibitors
History of atrial fibrillation or myocardial infarction
History of grade 4 hypertension, defined as hypertension resulting in life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis)
Chronic (duration >30 days) daily use of oral steroids
Known allergy to aspirin
Prior malignancy of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

Updated on 19 Feb 2024. Study ID: 1701922942 (A011502)

This study investigates whether aspirin can help prevent the return of cancer in patients with HER2 negative breast cancer. HER2 is a protein that can affect the growth of cancer cells. This study focuses on patients who have already received treatments like chemotherapy, surgery, or radiation therapy.

Participants will either receive aspirin or a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will compare the effects on invasive disease-free survival, which means living without the cancer coming back.

  • Who can participate: Adults diagnosed with stage II or III node-positive, HER2 negative breast cancer within the last year can participate. Participants must have completed chemotherapy or radiation therapy at least 60 days before joining.
  • Study details: Participants will be randomly assigned to take either aspirin or a placebo daily. They can use acetaminophen for minor pain.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here